Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PYPD - PolyPid Ltd.

Previous close
2.83
-0.120   -4.240%

Share volume: 100
Last Updated: Fri 27 Dec 2024 08:05:03 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%
$2.95
-0.12
-4.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 0%
Dept financing 16%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-22.55%
1 Month
-17.51%
3 Months
-21.27%
6 Months
-32.14%
1 Year
-28.75%
2 Year
-86.62%
Key data
Stock price
$2.83
P/E Ratio 
0.00
DAY RANGE
$2.95 - $2.95
EPS 
$0.00
52 WEEK RANGE
$2.53 - $9.20
52 WEEK CHANGE
-$25.00
MARKET CAP 
17.030 M
YIELD 
N/A
SHARES OUTSTANDING 
4.797 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$65,165
AVERAGE 30 VOLUME 
$43,739
Company detail
CEO: Dikla C. Akselbrad
Region: US
Website: polypid.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs)

Recent news